Home / Products / Genome-edited Cells / Hectd1 Knockout RAW 264.7 Cell Line

Hectd1 Knockout RAW 264.7 Cell Line

Cat. No. ARG43901
Product Type:

In Stock Cell Lines

Species:

Mus musculus (Mouse)

Tissue Source:

Ascites

Growth Properties:

Adherent

In stock
Request a Quote

Short Description

The Hectd1 Knockout RAW 264.7 Cell Line provides a CRISPR/Cas9-edited macrophage model for studying the E3 ubiquitin ligase Hectd1. It allows analysis of Hectd1??s ubiquitin-dependent degradation of substrates like Dvl2 and Hsp90, regulated by NF-??B via LPS, TNF-??, and IFN-??. Applications include inflammation signaling, macrophage migration, and drug target validation. This line is suited for co-immunoprecipitation, ubiquitinated protein Western blots, NF-??B reporter assays, cytokine ELISA, phagocytosis, and wound healing migration assays. For inquiries, contact Ascent Research.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Species:
Mus musculus (Mouse)
Tissue Source:
Ascites
Disease:
Leukemia
Growth Properties:
Adherent
Donor Age:
Adult
Donor Sex:
Male

Cell Engineering Information

Gene Name:
HECTD1
Gene Identifier:
NCBI Gene ID 207304

Immortalization Information

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Sterility testing:
The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description

The Hectd1 Knockout RAW 264.7 Cell Line is a CRISPR/Cas9-edited knockout cell line offering a loss-of-function model for the E3 ubiquitin ligase Hectd1 in a mouse macrophage background. This product is provided as a ready-to-use cell line, enabling dissection of Hectd1??s role in ubiquitin-dependent protein degradation and signaling without transient knockdown or chemical inhibition.

RAW 264.7 cells are derived from BALB/c mouse macrophages transformed with the Abelson murine leukemia virus, yielding an adherent line that responds to LPS and IFN-??. These cells exhibit robust phagocytosis, cytokine production, and antigen presentation, making them a standard innate immunity model. Their stable growth and genetic tractability facilitate knockout-based functional studies.

Hectd1 encodes an E3 ubiquitin ligase that catalyzes ubiquitin transfer from E2 conjugating enzymes to substrate proteins, tagging them for 26S proteasomal degradation or altering signaling. Known substrates include Hsp90 and Dvl2, linking Hectd1 to Wnt/planar cell polarity and TGF-?? pathways. It is regulated by NF-??B downstream of LPS, TNF-??, and IFN-??, and modulates Smad7 stability, thereby influencing Smad4-dependent transcription and ??-catenin/TCF responses.

In macrophages, Hectd1 knockout likely disrupts ubiquitin-dependent regulation of inflammatory mediators and cytoskeletal dynamics. Loss of Hectd1 may impair degradation of Dvl2 and Hsp90, altering Wnt/PCP-directed migration and NF-??B signaling termination, potentially dysregulating TNF-?? and IL-6 secretion and phagocytosis. This cell line serves as a relevant system to examine E3 ligase dysfunction in inflammation, neural tube defects, and cancer.

The knockout cell line supports applications such as co-immunoprecipitation for substrate interactions, Western blotting of ubiquitinated proteins, NF-??B luciferase reporter assays, and cytokine ELISA. Functional assays include fluorescent bead phagocytosis, wound healing migration, and flow cytometry for surface markers during polarization. These enable investigation of E3 ligase function in immune cells, ubiquitin-dependent signaling in inflammation, and drug target validation. For further information, contact Ascent Research.